SCHEMBL3976519

SCHEMBL3976519

NNC(=O)c1occc1-c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
GSTP1 P09211 1/20 0.44
TP53 P04637 1/20 0.44
KDM4E B2RXH2 1/20 0.42
GALR3 O60755 1/20 0.41
GAA P10253 1/20 0.41
PARP10 Q53GL7 1/20 0.41
PGR P06401 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3978096 0.88 MEN1 (0.50) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL4285451 0.87 MAPT (0.43) MEN1MAPTKMT2AALDH1A1KDM4E
SCHEMBL3977386 0.84 MAPT (0.52) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL27605289 0.84 GSTP1 (0.50) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL3979527 0.82 KMT2A (0.51) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL3976016 0.82 MEN1 (0.43) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL3982394 0.80 ALDH1A1 (0.37) MEN1KMT2ALMNAALDH1A1HPGD
SCHEMBL3983418 0.80 PORCN (0.50) NPC1RAB9ASMN1; SMN2MEN1MAPT
SCHEMBL3982443 0.80 NPSR1 (0.43) MEN1MAPTKMT2ALMNAALDH1A1
SCHEMBL141046 0.79 MAPT (0.37) SMN1; SMN2MEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 NPC1 1584/4885RAB9A 2501/4885SMN1; SMN2 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.